Hepatocellular Cancer

P=N/A, N=64, Not yet recruiting, University of California, San Francisco | Trial completion date: Dec 2028 --> Mar 2029 | Initiation date: May 2026 --> Oct 2026 | Trial primary completion date: Dec 2028 --> Mar 2029

P3, N=214, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting | Trial completion date: Mar 2025 --> Sep 2026 | Trial primary completion date: Mar 2025 --> Sep 2026

P=N/A, N=50, Recruiting, University of California, San Diego | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2026 --> Dec 2027

Pathway enrichment analysis suggested that the potential target genes of hsa-miR-103a-3p were mainly enriched in AMP-activated protein kinase, mechanistic target of rapamycin, tumor necrosis factor, insulin signaling, and cellular senescence pathways...These findings suggest that adult S. japonicum worms may alter the miRNA expression profile of hepatic stellate cells, and that hsa-miR-103a-3p may be associated with fibrogenic responses and may have potential relevance to hepatocellular carcinoma-related processes. However, this inference is based on correlative TCGA data and does not imply a causal role in schistosomiasis-associated hepatocarcinogenesis.

Circulating miRNA-155 is markedly upregulated in HCV-related HCC and correlates strongly with disease progression. The novel HCC-miR Score represents a simple, sensitive, and noninvasive model for the early diagnosis of HCC in high-risk HCV patients.

Despite the therapeutic potential of the gut microbiota-polysaccharide-liver TME axis, several challenges remain, including polysaccharide structural heterogeneity, unclear microbiota-immune causal relationships, and undefined safe dose windows. Overall, this review provides an integrated overview of polysaccharide-based modulation of the HCC immune microenvironment and may offer insights for the development of more precise therapeutic strategies according to HCC etiological heterogeneity.

No obvious toxic reaction was observed. By activating STING/TBK1/IRF3 signaling, TET enhanced CD8+ T cell-mediated anti-tumor immunity, thereby markedly enhancing anti-PD-1 therapy efficacy in HCC.

This review systematically summarizes the molecular characteristics, expression regulation, physiological functions, and mechanisms of OTUD7B in neoplastic and non-neoplastic diseases. It also discusses the prospects and challenges of its clinical translation.

IL-6 was closely associated with HBV DNA levels, while the association with conventional biochemical markers of hepatocellular injury was significantly less in this cohort, suggesting that IL-6 may serve as an adjunct biomarker of disease activity in patients with chronic hepatitis B.

P3, N=115, Active, not recruiting, NRG Oncology | N=186 --> 115 | Trial completion date: Jun 2027 --> Feb 2027

BRGi-39 is identified as a novel and highly selective BRG1-BRD inhibitor that effectively overcomes chemoradioresistance in HCC by dismantling the DDR pathway. Our comprehensive preclinical data highlight BRGi-39 as a promising, safe therapeutic candidate to be combined with chemoradiotherapy for the treatment of unresectable HCC.

RIG-I activation via 3p-RNA therapy shows promise as an immunotherapeutic strategy for hepatocellular carcinoma (HCC). Future investigations need to focus on tumor-intrinsic factors to understand heterogeneity between tumors and to overcome resistance mechanisms.